Sie suchten nach: metotreksat (Litauisch - Englisch)

gydantis humira, toliau vartoti metotreksat.
methotrexate should be continued during treatment with humira.

-metotreksat (gydoma reumatoidinis artritas ir vzys);
-if you have established heart disease and/or cerebrovascular disease eg. if you have had a heart

nuo reumato (lemvr) , skaitant metotreksat, buvo neskmingas;
(dmards) , including methotrexate, has been inadequate.

modifikuojanci vaist nuo reumato, skaitant ir metotreksat, poveikis nepakankamas.
inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. t

kineret skiriamas pacientams, kuri atsakas metotreksat nepakankamas reumatoidiniam artritui kontroliuoti.
kineret is for patients whose response to methotrexate on its own is not good enough to control the rheumatoid arthritis.

bab ir psb skirtumai, vartojant metotreksat ir 25 mg enbrel nebuvo statistiskai reiksmingi.
the differences in tss and jsn were not statistically significant between methotrexate and enbrel 25 mg.

brb ir psb skirtumai, vartojant metotreksat ir 25 mg enbrel, nebuvo statistiskai reiksmingi.
the differences in tss and jsn were not statistically significant between methotrexate and enbrel 25 mg.

maziau nei 3 metus reumatoidiniu artritu sirgusi ir enbrel arba metotreksat vartojusi pacient lyginamieji duomenys
comparison of enbrel vs methotrexate in patients with ra of 3 years duration

maziau nei 3 metus reumatoidiniu artritu sirgusi ir enbrel arba metotreksat vartojusi pacient lyginamieji duomenys pokytis nuo pradinio rodmens
comparison of enbrel vs methotrexate in patients with ra of 3 years duration

kineret rekomenduojama skirti drauge su metotreksatu reumatoidinio artrito pozymiams ir simptomams gydyti, kai pacient atsakas vien metotreksat nepakankamas.
kineret is indicated for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone.

apie derinim su kitais, isskyrus metotreksat, lig modifikuojanciais antireumatiniais vaistais zr.4. 4 ir 5. 1 skyrius.
regarding combination with disease modifying anti-rheumatic drugs other than methotrexate see sections 4.4 and 5.1.

lyginant su gavusi vien tik metotreksat pacient grupe, infliksimab kartu su metotreksatu gavusij grupje 30 ir 54 savait buvo stebimas struktrini pazeidim progresavimo sumazjimas.
reduction in the rate of progression of structural damage was observed at weeks 30 and 54 in the infliximab + methotrexate groups compared to methotrexate alone.

jeigu jums yra vidutinio sunkumo ar sunkus aktyvus reumatoidinis artritas, pirmiausia gali paskirti kit, lig modifikuojant vaist, pvz., metotreksat.
if you have moderate to severe active rheumatoid arthritis, you may first be given other disease-modifying medicines, such as methotrexate.

be uzdegimo ar analgetikus.apie derinim su kitais, isskyrus metotreksat, lig modifikuojanciais antireumatiniais vaistais zr.4. 4 ir 5. 1 skyrius.
regarding combination with disease modifying anti-rheumatic drugs other than methotrexate see sections 4.4 and 5.1. no

keturiuose tyrimuose (kuriuose dalyvavos 2 000 pacient) vieno arba kartu su kitais vaistais nuo uzdegimo (skaitant metotreksat) vartojamo
in four of these studies (involving over 2,000 patients) , the effectiveness of

pirmojo aktyviai kontroliuojamo tyrimo metu sunks nepageidaujami reiskiniai nustatyti 6% is 415 pacient, vartojusi enbrel, ir 8% is 217 pacient, vartojusi metotreksat.
in the first active-controlled trial, serious adverse events occurred at a frequency of 6% in 415 patients treated with enbrel compared with 8% of 217 methotrexate-treated patients.

vi tyrimo, trukusio 24 savaites, metu, buvo gydomi 313 suaugusi pacient, kuri atsakas gydym nesteroidiniais priesuzdegiminiais vaistais buvo nepakankamas, is j ­ apie 50% vartojo metotreksat.
study vi with 24 week duration, treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy and of these, approximately 50% were taking methotrexate.

tiriant sveik reumatoidiniu artritu sergantiems pacientams, vartojantiems metotreksat vien kart per savait raumenis, geriamas valdekoksibas (40 mg 2 kartus per dien) nesukl klinikoje reiksmingo poveikio metotreksato koncentracijai plazmoje.
in interaction studies in rheumatoid arthritis patients receiving weekly methotrexate intramuscularly, orally administered valdecoxib (40 mg twice daily) did not have a clinically significant effect on the plasma concentrations of methotrexate.

dazniausiai pacientai, sergantys reumatoidiniu artritu, krono liga, opiniu kolitu, ankiloziniu spondilitu, psoriaziniu artritu arba psoriaze, jau vartoja kelet vaist sioms ligoms gydyti, pavyzdziui, metotreksat, azatioprin ar 6-merkaptopurin.
generally, patients who have rheumatoid arthritis, crohn 's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis, already take several medicines to treat their disease such as methotrexate, azathioprine or 6-mercaptopurine.